Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05090345
Other study ID # Pro00112697
Secondary ID NCI-2021-11324
Status Recruiting
Phase
First received
Last updated
Start date November 19, 2019
Est. completion date February 5, 2026

Study information

Verified date March 2024
Source Duke University
Contact LaTarsha Spencer
Phone (919) 613-1895
Email latarsha.spencer@duke.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective international multi-center registry and biorepository trial of children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.


Description:

Primary: - To evaluate the proportion of pediatric patients undergoing hematopoietic cell transplant (HCT) who develop endotheliopathies (SOS, TMA, DAH and IPS) and/or MODS within 100 days of such therapies. - To evaluate the proportion of pediatric patients undergoing hematopoietic cell transplant (HCT) who experience abnormal levels of circulating angiogenic, vascular permeability and inflammatory factors within 100 days post HCT-CT in the setting of endotheliopathies. Secondary/Exploratory Objective(s): - To determine the impact of endotheliopathies in the HCT setting on the overall survival. - To assess the efficacy of specific prophylaxis and treatment strategies directed at endotheliopathies (SOS, TMA, DAH and IPS) post-HCT among enrolled children on overall survival. - To assess whether exposure to immunotherapies (CAR-T, PD-1 Inhibitors, bispecific T-cell engager (BiTE) antibodies and antibody drug conjugates) prior to HCT affects post-HCT outcomes (endotheliopathies and MODS).


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date February 5, 2026
Est. primary completion date February 5, 2026
Accepts healthy volunteers No
Gender All
Age group 0 Years to 26 Years
Eligibility Inclusion Criteria: - Children, adolescents and young adults (AYA) 0-26 years of age undergoing HSCT. - Recipients of autologous and allogeneic HSCT. - Any preparative regimen. Exclusion Criteria: - Any patient who does not consent/assent to participation. - Any patient for whom 5 mL blood sample(s) drawn at specified intervals would pose any more than minimal risk, as defined by institutional guidelines and at discretion of treating physician will be ineligible for biorepository banking.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Biorepository Trial
participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.

Locations

Country Name City State
United States Duke University Durham North Carolina
United States MD Anderson Cancer Center Houston Texas
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of pediatric patients undergoing hematopoietic cell transplant (HCT) who develop endotheliopathies (SOS, TMA, DAH and IPS) and/or MODS within 100 days of such therapies. through study completion, an average of 1 year
Primary Proportion of pediatric patients undergoing (HCT) who experience abnormal levels of circulating angiogenic factors within 100 days post HCT-CT in the setting of endotheliopathies. through study completion, an average of 1 year
Primary Proportion of pediatric patients undergoing (HCT) who experience abnormal levels of vascular permeability within 100 days post HCT-CT in the setting of endotheliopathies. through study completion, an average of 1 year
Primary Proportion of pediatric patients undergoing (HCT) who experience abnormal levels of inflammatory factors within 100 days post HCT-CT in the setting of endotheliopathies. through study completion, an average of 1 year
Secondary Overall survival. through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03179761 - High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients Phase 2
Recruiting NCT05634512 - Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.
Completed NCT05600101 - Development and Piloting an Avatar-based Intervention to Support Patients Undergoing Stem Cell Transplantation N/A
Recruiting NCT05866302 - Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
Completed NCT04139577 - FMT In High-Risk Acute GVHD After ALLO HCT Phase 1
Completed NCT04727827 - Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation N/A

External Links